Trial Search Results

Imaging and Biomarkers of Hypoxia in Solid Tumors

Hypoxia, meaning a lack of oxygen, has been associated strongly with a wide range of human cancers. Hypoxia occurs when tumor growth exceeds the ability of blood vessels to supply the tumor with oxygenated blood. It is currently understood that hypoxic tumors are more aggressive. Current methods for measuring hypoxia include invasive procedures such as tissue biopsy, or insertion of an electrode into the tumor. EF5-PET may be a non-invasive way to measure tumor hypoxia.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Intervention(s):

  • Procedure: PET Scan
  • Drug: EF5
  • Drug: Carbogen
  • Drug: Dichloroacetate

Phase:

Phase 1

Eligibility


INCLUSION CRITERIA

   - Any solid tumor malignancies of any stage meeting all of the following criteria:
   Minimum tumor dimension is at least 1 cm (to ensure it is above the detection
   threshold of PET imaging). Examples include but are not limited to: locally advanced
   squamous cell carcinoma of the head and neck to be treated by either initial surgery
   or primary chemoradiotherapy; inoperable non-small cell lung cancer or pancreatic
   carcinoma to be treated with stereotactic radiotherapy, which may be biopsied again at
   the time of percutaneous needle delivery of implanted fiducial markers.

   - Patients with newly diagnosed malignancies should not have initiated treatment for
   their disease before participating in this study. Patients with recurrent or second
   malignancies may have had prior therapy as appropriate for their disease, but should
   have completed all prior treatment at least 30 days before participation in this study
   and should not have initiated new treatment for the current problem.

   - Greater than or equal to eighteen years of age.

   - Sufficiently healthy to tolerate all study procedures.

   - Organ and marrow function sufficient to undergo planned therapy.

   - Ability to understand and the willingness to sign a written informed consent document.

EXCLUSION CRITERIA

• Pregnant or nursing

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061